Indiana-based BioCrossroads has launched an $8.25m early-stage capital fund focused on identifying, creating and developing life sciences companies.
A follow-on to a $6m first fund, Indiana Seed Fund II will invest an average of $500k in early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech and health information technology products and platforms.
It will be managed by BioCrossroads’ professional team.
The fund is a result of a public-private collaboration of corporate, university and philanthropic investors including:
– BC Initiative (BioCrossroads’ for-profit/investment entity),
– Eli Lilly and Company,
– the Richard M. Fairbanks Foundation, Inc.,
– Indiana University Research and Technology Corporation,
– Purdue University,
– the University of Notre Dame, and